These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30763284)

  • 1. Healthcare Resource Utilization and Cost of Invasive Meningococcal Disease in Ontario, Canada.
    Rampakakis E; Vaillancourt J; Mursleen S; Sampalis JS
    Pediatr Infect Dis J; 2019 Mar; 38(3):253-257. PubMed ID: 30763284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database.
    Huang L; Heuer OD; Janßen S; Häckl D; Schmedt N
    PLoS One; 2020; 15(1):e0228020. PubMed ID: 31990941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children.
    Wang B; Haji Ali Afzali H; Marshall H
    Vaccine; 2014 Aug; 32(37):4791-8. PubMed ID: 24998605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost impact of complications in meningococcal disease: evidence from a United States managed care population.
    Davis KL; Misurski D; Miller J; Karve S
    Hum Vaccin; 2011 Apr; 7(4):458-65. PubMed ID: 21795848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
    Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
    Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of meningococcal disease in children and adolescents in Tijuana, Mexico.
    Chacon-Cruz E; Lopatynsky-Reyes EZ; Huerta-Garcia G; Cervantes-Apolinar MY; Guzman-Holst A; Van Oorschot D
    Hum Vaccin Immunother; 2022 Nov; 18(6):2103319. PubMed ID: 35921223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of patients with Cushing's disease: a Canadian cost of illness analysis.
    Uum SV; Hurry M; Petrella R; Koch C; Dranitsaris G; Lacroix A
    J Popul Ther Clin Pharmacol; 2014; 21(3):e508-17. PubMed ID: 25527801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost and public health burden of invasive meningococcal disease outbreaks: a systematic review.
    Anonychuk A; Woo G; Vyse A; Demarteau N; Tricco AC
    Pharmacoeconomics; 2013 Jul; 31(7):563-76. PubMed ID: 23673904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct cost associated with acquired brain injury in Ontario.
    Chen A; Bushmeneva K; Zagorski B; Colantonio A; Parsons D; Wodchis WP
    BMC Neurol; 2012 Aug; 12():76. PubMed ID: 22901094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospital costs, length of stay and mortality associated with childhood, adolescent and young adult meningococcal disease in the US.
    Davis KL; Bell TJ; Miller JM; Misurski DA; Bapat B
    Appl Health Econ Health Policy; 2011 May; 9(3):197-207. PubMed ID: 21506625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex.
    Stoof SP; Rodenburg GD; Knol MJ; Rümke LW; Bovenkerk S; Berbers GA; Spanjaard L; van der Ende A; Sanders EA
    Clin Infect Dis; 2015 Oct; 61(8):1281-92. PubMed ID: 26123933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare resource utilization and related cost among hospitalized patients with prurigo nodularis: a retrospective cohort study using Italian health claims data.
    Bahloul D; Ronci G; Isaman DL; Pedone MP; Degli Esposti L; Giacomini E; Veronesi C; Patruno C; Chiricozzi A; Amerio P
    Ital J Dermatol Venerol; 2024 Oct; 159(5):475-483. PubMed ID: 39250164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory virus infection and risk of invasive meningococcal disease in central Ontario, Canada.
    Tuite AR; Kinlin LM; Kuster SP; Jamieson F; Kwong JC; McGeer A; Fisman DN
    PLoS One; 2010 Nov; 5(11):e15493. PubMed ID: 21103353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of Invasive Meningococcal Disease: A Global Systematic Review.
    Wang B; Santoreneos R; Afzali H; Giles L; Marshall H
    Pharmacoeconomics; 2018 Oct; 36(10):1201-1222. PubMed ID: 29948965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public health management of invasive meningococcal disease in Baden-Wuerttemberg, Germany, 2012: adherence to guidance and estimation of resources required as determined in a survey of local health authorities.
    Murajda L; Aichinger E; Pfaff G; Hellenbrand W
    BMC Public Health; 2015 Apr; 15():371. PubMed ID: 25881238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating direct healthcare costs attributable to laboratory-confirmed Lyme disease in Ontario, Canada: A population-based matched cohort study using health administrative data.
    Shing E; Wang J; Khoo E; Evans GA; Moore S; Nelder MP; Patel SN; Russell C; Sider D; Sander B
    Zoonoses Public Health; 2019 Jun; 66(4):428-435. PubMed ID: 30665259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US.
    Davis KL; Misurski D; Miller JM; Bell TJ; Bapat B
    Hum Vaccin; 2011 Jan; 7(1):96-101. PubMed ID: 21278486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resource Utilization and Costs in Adolescents Treated for Cancer in Pediatric vs Adult Institutions.
    Nathan PC; Bremner KE; Liu N; Gupta S; Greenberg ML; McBride ML; Krahn MD; de Oliveira C
    J Natl Cancer Inst; 2019 Mar; 111(3):322-330. PubMed ID: 30053118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A database study of clinical and economic burden of invasive meningococcal disease in France.
    Huang L; Fievez S; Goguillot M; Marié L; Bénard S; Elkaïm A; Tin Tin Htar M
    PLoS One; 2022; 17(4):e0267786. PubMed ID: 35486581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resource utilization for acute lower gastrointestinal hemorrhage: the Ontario GI bleed study.
    Comay D; Marshall JK
    Can J Gastroenterol; 2002 Oct; 16(10):677-82. PubMed ID: 12420025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.